YUFLYMA

GrowthmAb

adalimumab-aaty

BLAINJECTIONINJECTABLE
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1

Clinical Trials (1)

NCT05427942N/AUnknown

Yuflyma® (Adalimumab), Patient Experience After Switching

Started Jun 2022
300 enrolled
Rheumatoid ArthritisAnkylosing SpondylarthritisAxial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis+3 more